The Right Drug Dose Now Act of 2024 aims to improve how the healthcare system uses genetic testing to prevent harmful drug reactions. The bill requires the Department of Health and Human Services to update the National Action Plan for Adverse Drug Event Prevention to incorporate advances in pharmacogenomic research, which studies how a person's genes affect their response to medications. The legislation also directs the agency to issue guidance to healthcare providers about pharmacogenomic testing and to work with electronic health record systems to automatically alert doctors when genetic testing is appropriate or when a patient's genes indicate they should not take a particular medication. Additionally, the bill requires improvements to the FDA's adverse event reporting system to make it easier for patients and providers to report drug reactions, and it mandates several reports to Congress within 180 days to 1 year on implementation progress. The legislation is intended to help ensure patients receive the right medication at the right dose based on their genetic makeup.